MediWound Ltd.

EscharEx's Phase 3 trial is progressing with enrollment completion and an interim assessment expected by end of Q1 2027. The active wound care market is projected to grow from $7.8 billion in 2025 to $15.9 billion by 2036, representing a massive commercial opportunity for MediWound's pipeline asset.

The Phase 3 trial timeline has been pushed back, with enrollment completion now expected only by Q1 2027. Delays in late-stage trials introduce execution risk and uncertainty around when — or whether — EscharEx will reach commercial approval and generate meaningful revenue.

MediWound expects government stockpiling orders for NexoBrid to begin lifting its own revenue in the second half of 2026. Cathie Wood's ARK fund has taken a notable position, likely attracted by this combination of a commercially active, government-backed asset alongside a late-stage pipeline candidate.

Expected revenue for Q2 2026 stands at a modest $2.59 million, underscoring MediWound's heavy dependence on lumpy, unpredictable government procurement cycles. Reliance on stockpiling orders — rather than consistent commercial demand — makes revenue visibility poor and financial planning difficult.

Technical analysis indicates a general buy signal, with long-term moving averages trending positively and a pivot bottom buy signal issued in late June 2025. The stock is projected to rise approximately 7.68% over the next three months, with a 90% probability of trading between $21.12 and $25.03.

Despite positive long-term trend signals, short-term moving averages have issued a sell signal, and the stock faces resistance near $20.47. Low liquidity periods increase general risk, and the stock's price has already declined significantly from earlier levels, with Q2 2026 pricing around $14.68.